Clinical trial

Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC

NCT06258642

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2024-04-17

PhaseNA

Study timeline

Study start (actual)2024-04-17Date precision: day

Registry last updated2025-08-20

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Small Cell Lung Cancer Recurrentunresolved

Interventions

Irinotecan LiposomeDRUG

AnlotinibDRUG

Sponsors & collaborators

Fudan Universitylead sponsor

Mapped research locations

ShanghaiShanghai Municipality, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06258642 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.